KILLEVIR - anti-HIV mono-therapy drug, based on by Fullerene-poly- aminocaproic acid
The sub-division of KILLEVIR is currently undergoing tests against the COVID-19 in vitro in NIH USA
To develop the medically-focused pitch deck for the specialized VC’s
To speak out the project uniqueness and strongly communicate its key message in the saturated visual image of HIV in the world